BMY
ELTX
A small clinical win, but the kind investors like
Elicio Therapeutics just tossed a fresh spark onto a pretty tricky cancer story. The company said three patients from its Phase 2 AMPLIFY-7P study later achieved confirmed complete responses after receiving Bristol-Myers Squibb’s Opdivo-based therapy, with two responses lasting at least eight months and one still going past 13 months.
That matters because pancreatic cancer is usually a brutal battleground where the immune system doesn’t exactly show up ready to party. So when Elicio points to persistent mKRAS-specific T-cell responses, the pitch is basically: maybe this vaccine-ish approach helps make checkpoint therapy work better than it otherwise would.
Why the stock is popping
The market loves a good “maybe this is the real mechanism” story, especially in oncology. Elicio shares jumped 28.8% to $3.55 as traders latched onto the durability of those responses and the idea that the drug could be useful in combination regimens.
But there’s a catch: the earlier AMPLIFY-7P study still missed its pre-specified primary endpoint of disease-free survival in the intent-to-treat population. Translation: this is encouraging, but not yet a victory lap. It’s more like finding a promising shortcut on the map, not arriving at the destination.
What’s next
Subject to funding, Elicio plans to start a Phase 1 combo study in treatment-naïve metastatic mKRAS pancreatic cancer, pairing ELI-002 7P with gemcitabine/nab-paclitaxel and an anti-PD-1 inhibitor.
That’s the real investor question now: can these subgroup signals turn into a cleaner, prospective readout that actually changes how the drug gets developed? Big picture: the science is still in the “show me” phase, but today’s data gave Elicio enough fuel to keep the pipeline story alive.